Episode

Spotlight at Guidelines on Continuous Glucose Monitoring in Type 2 Diabetes

Podcast
Diabetes Insights - Breakthroughs and Innovators
Published
Jun 19, 2026
Duration seconds
517
Processing state
not_requested
Canonical source
https://diabetes-insights.podigee.io/68-spotlight-at-guidelines-on-continuous-glucose-monitoring-in-type-2-diabetes
Audio
https://audio.podigee-cdn.net/2524553-m-f3f84b57dbbf7b4d90dcc0eea6a8478a.mp3?source=feed
JSON
/v1/public/podcasts/diabetes-insights-breakthroughs-and-innovators-7109701/episodes/spotlight-at-guidelines-on-continuous-glucose-monitoring-in-type-2-diabetes
Markdown
/podcast/diabetes-insights-breakthroughs-and-innovators-7109701/spotlight-at-guidelines-on-continuous-glucose-monitoring-in-type-2-diabetes.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/diabetes-insights-breakthroughs-and-innovators-7109701/episodes/spotlight-at-guidelines-on-continuous-glucose-monitoring-in-type-2-diabetes/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/diabetes-insights-breakthroughs-and-innovators-7109701/spotlight-at-guidelines-on-continuous-glucose-monitoring-in-type-2-diabetes.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

In this episode, Dame Melanie Davies and Prof. Amanda Adler discuss the development of a new EASD clinical guideline on continuous glucose monitoring (CGM) in people living with type 2 diabetes. As CGM becomes increasingly available, clinicians, researchers, and policymakers are seeking clear evidence-based guidance on its role in diabetes management. The discussion explores why CGM was selected as a priority topic, how guideline questions are developed, the importance of patient involvement, and the rigorous process used to evaluate clinical evidence. The conversation also highlights the broader outcomes that matter to people living with diabetes (including quality of life, confidence and behaviour change) and examines how future recommendations could influence healthcare policy and access to diabetes technology across Europe and beyond.